Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Combinations vs Sunitinib in First-Line Advanced RCC (CLEAR)
NCT02811861Phase 3Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of lenvatinib in renal cell carcinoma (RCC), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-Free Survival at 46 months. Started Oct 2016; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02811861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811861.